"Buprenorphine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A derivative of the opioid alkaloid THEBAINE that is a more potent and longer lasting analgesic than MORPHINE. It appears to act as a partial agonist at mu and kappa opioid receptors and as an antagonist at delta receptors. The lack of delta-agonist activity has been suggested to account for the observation that buprenorphine tolerance may not develop with chronic use.
| Descriptor ID |
D002047
|
| MeSH Number(s) |
D03.132.577.249.150 D03.605.497.150 D03.633.400.686.150 D04.615.723.795.150
|
| Concept/Terms |
Subutex- Subutex
- Buprex
- Temgesic
- Temgésic
6029-M- 6029-M
- 6029 M
- 6029M
- RX-6029-M
- RX 6029 M
- RX6029M
|
Below are MeSH descriptors whose meaning is more general than "Buprenorphine".
Below are MeSH descriptors whose meaning is more specific than "Buprenorphine".
This graph shows the total number of publications written about "Buprenorphine" by people in this website by year, and whether "Buprenorphine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 1 | 1 | 2 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 5 | 1 | 6 |
| 2021 | 4 | 1 | 5 |
| 2022 | 4 | 0 | 4 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Buprenorphine" by people in Profiles.
-
Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023 01 01; 80(1):84-92.
-
Assessing Opioid Use Disorder Treatments in Trials Subject to Non-Adherence via a Functional Generalized Linear Mixed-Effects Model. Int J Environ Res Public Health. 2022 04 29; 19(9).
-
Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. Int J Environ Res Public Health. 2022 03 30; 19(7).
-
A retrospective, observational study on medication for opioid use disorder during pregnancy and risk for neonatal abstinence syndrome. Fam Pract. 2022 03 24; 39(2):311-315.
-
A Retrospective Study of Acute Postoperative Pain After Cesarean Delivery in Patients With Opioid Use Disorder Treated With Opioid Agonist Pharmacotherapy. J Addict Med. 2022 Sep-Oct 01; 16(5):549-556.
-
The development and implementation of a "B-Team" (buprenorphine team) to treat hospitalized patients with opioid use disorder. Healthc (Amst). 2021 Dec; 9(4):100579.
-
Effectiveness of a substance use treatment program for veterans with chronic pain and opioid use disorder. J Subst Abuse Treat. 2022 01; 132:108635.
-
Retention in Treatment after Emergency Department-Initiated Buprenorphine. J Emerg Med. 2021 09; 61(3):211-221.
-
Design and methods of a multi-site randomized controlled trial of an integrated care model of long-acting injectable buprenorphine with infectious disease treatment among persons hospitalized with infections and opioid use disorder. Contemp Clin Trials. 2021 06; 105:106394.
-
Leveraging Telehealth in the United States to Increase Access to Opioid Use Disorder Treatment in Pregnancy and Postpartum During the COVID-19 Pandemic. Am J Psychiatry. 2021 04 01; 178(4):290-293.